Monthly Archives: September 2016

Thermalabs Shea Body Butter Joins List of the Company’s Bestselling Products

One of Thermalabs latest launches, the Shea Body Butter, has emerged a bestseller.

New York, United States – September 28, 2016 /MarketersMedia/ —

Thermalabs has said that one of its latest products, the Shea Body Butter, has joined its list of all-time bestsellers. The product currently ranks number 6 on the company’s list of top-grossing products. Considering that Shea Body Butter was introduced just a few weeks ago, this is no mean achievement. It demonstrates a top-quality product that’s able to meet users’ expectations, as well as deliver on its promise.

Thermalabs is a leading cosmetics firm based in the United States. The company’s headquarters are located in New York City, but it operates a number of production facilities in other parts of the world. Thermalabs opened its doors nearly three years ago, starting out with a self-tanning lotion that was known as the ‘Gold Standard Tanner’. The product was created from a combination of natural and organic ingredients. It was able to deliver an impressive tan barely 4 hours after being applied on the skin. Considered that most of the existing tanners took up to 6 hours to show results, this was something quite new. Thermalabs, then a little-known startup, was able to highlight the unique benefits of its product over the competition. Following an intensive pre-launch marketing run, Thermalabs pilot product sold over 1000 units within 24 hours on Amazon.com alone.

Thermalabs has today introduced nearly 30 different products. Most of these are tanning lotions and accessories. In recent times, the company appears to be drifting towards beach-related products. Thermalabs introduced its first beach tent in December last year. This is a shielded, extra-comfy tent that served as the ideal spot for beach-goers to hide or relax after spending some fun time in the water. The product kept the occupants’ skin protected from harmful UV radiation from the sun, and was designed to be extremely easy to use.

Thermalabs Shea Body Butter was introduced a few weeks ago under the Supremasea sub-brand. This is a triple moisturizing lotion designed for individuals suffering from stretch marks, dry skin, and scars. It includes a special regimen of Dead Sea salts, combined with conventional ingredients that are known to be highly beneficial for the skin. Thermalabs has been marketing this product for the last few weeks, highlighting its unique benefits and comparing them to the shortcomings of the competition’s products.

Alex Howard, a marketing coordinator at Thermalabs, said, “Barely 7 weeks after we launched our Shea Body Butter formula, we are delighted to say that it’s joined our list of top 10 bestsellers across all marketplaces. This product comes sixth after the likes of Glow2Go, Ultimitt, Original Self Tanner and Beach Tent. This is an extraordinary milestone for a Supremasea product, and it highlights that this formulation is able to deliver on its promise. It’s our goal to design problems that will help our customers overcome various problems. Shea Body Butter not only seems to be headed in the right direction, but it is also setting new bottom-lines for our marketing efforts. It’s setting the way for upcoming Supremasea products…”

For more information, please visit http://www.thermalabs.com/home

Contact Info:
Name: James Crothers
Organization: Thermalabs
Address: 450 West 58th Street New York, NY 10019
Phone: (877) 266-6257

Video URL: https://www.youtube.com/watch?v=f-gBGXC2aPg

Source: http://marketersmedia.com/thermalabs-shea-body-butter-joins-list-of-the-companys-bestselling-products/134825

Release ID: 134825

MAXBURST Now Offering New York City Web Design Company Services in NYC

MAXBURST, Inc. releases information on how its new New York City Web Design Company Services will change things in the corporate web design space for the better. Further information can be found at https://www.maxburst.com.

Farmingdale, United States – September 28, 2016 /PressCable/ —

Earlier today, MAXBURST, Inc. announced the launch of its new New York City Web Design Company services, set to go live Monday, October 3, 2016. For anyone with even a passing interest in the world of corporate web design, this new development will be worth paying attention to, as it’s set to shake things up.

Anyone who has solicited website design quotes recently will notice most web design companies offer nothing but cookie cutter design templates. The Co-Founder at MAXBURST, Inc., Andrew Ruditser, makes a point of saying “things are going to change when our New York City Web Design service launches”.

Andrew Ruditser continues… “Where you’ll always see our competitors doing the same old thing, we will work with our clients to develop a completely custom website that exceeds their expectations. We do this because we believe our goal is to make you stand out with style and be remembered. Ultimately this is going to be a huge benefit to our customers because it will help to generate more revenue, get more customers and increase profit margins.”

MAXBURST, Inc. was established in 2007. It has been doing business for ten years now and it has always aimed to become the Top Rated New York City Web Design Company.

Currently, the closest thing to MAXBURST, Inc.’s New York City Web Design service is the traditional print media and public relations industry, but MAXBURST, Inc. improved on this by by providing their clients the ability to standout as unique within their industry in the digital realm. This alone is predicted to make MAXBURST, Inc.’s New York City Web Design service more popular with customers in the corporate web design space, quickly.

Once again, the New York City Web Design Company service is set to launch Monday, October 3, 2016. To find out more, the place to visit is https://www.maxburst.com

For more information, please visit https://www.maxburst.com

Contact Info:
Name: Andrew Ruditser
Email: info@maxburst.com
Organization: MAXBURST, Inc.
Address: 565 Broadhollow Rd Suite 12E
Phone: (631) 293-9100

Release ID: 134698

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tokai Pharmaceuticals, Inc. (TKAI) and Lead Plaintiff Deadline: September 30, 2016

NEW YORK, NY / ACCESSWIRE / September 28, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against of Tokai Pharmaceuticals, Inc. (“Tokai” or the “Company”) (NASDAQ: TKAI). The class is on behalf of a class consisting of all persons or entities who purchased Tokai from June 24, 2015 through July 25, 2016, inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

Tokai Pharmaceuticals is a company focused on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases. Galeterone, Tokai’s lead drug candidate, is an oral small molecule that was used in various clinical trials for the treatment of patients with metastatic castration-resistant prostate cancer.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Tokai’s business, operational and compliance policies. Particularly, Defendants made false and/or misleading statements and/or failed to disclose that: (1) there were noteworthy structural problems with ARMOR3-SV, the trial design for Tokai’s pivotal Phase 3 Galeterone study, (2) accordingly, ARMOR3-SV would probably not meet its primary endpoint; (3) therefore, the likelihood of Galeterone’s commercialization was not as probable as Tokai had told investors; and (4) consequently, Tokai’s financial statements, and Defendants’ statements regarding Tokai’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On November 2, 2015, Seeking Alpha published a report by Richard Pearson, “What’s Wrong With Tokai Pharmaceuticals?”. The article described structural problems with the design of the Company’s ARMOR3-SV trial. Following this news, Tokai stock dropped $0.07 per share, or 0.63%, to close at $10.98 on November 2, 2015.

Then, on July 26, 2016, Tokai said it would “discontinue the ARMOR3-SV clinical trial, our pivotal Phase 3 study” of Galeterone. Directly following this news, Tokai stock dropped $4.10 per share, or roughly 79%, to close at $1.10 on July 26, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action please visit the firm’s site: http://www.bgandg.com/#!tkai/wnom2 or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Tokai you have until September 30, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 443235

SHAREHOLDER ALERT – Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Concordia International Corp (CXRX) & Lead Plaintiff Deadline: October 14, 2016

NEW YORK, NY / ACCESSWIRE / September 28, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Concordia International Corp (“Concordia” or the “Company”) (NASDAQ: CXRX) and certain of its officers. The class action is on behalf of a class consisting of all persons or entities who purchased Concordia securities between November 12, 2015 through August 12, 2016, inclusive (the “Class Period”).

According to the Complaint, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Concordia was suffering a surge in market competition against its drug, Donnatal, and other of its primary products; (2) therefore, Concordia’s financial results be affected and Concordia would have to suspend its dividend; and (3) consequently, defendants’ statements regarding Concordia’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/cxrx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Concordia you have until October 14, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 443890

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against SunPower Corp. (SPWR) & Lead Plaintiff Deadline: October 17, 2016

NEW YORK, NY / ACCESSWIRE / September 28, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against SunPower Corp. (“SunPower” or the “Company”) (NASDAQ: SPWR) and certain of its officers. The class action is on behalf of a class consisting of all persons or entities who purchased SunPower securities between February 17, 2016 through August 9, 2016, inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

SunPower is and American energy company that designs and manufactures sustainable energy products to residential customers, businesses, and institutions.

On August 9, 2016, SunPower released its second quarter 2016 financial results. SunPower did meet some of its projected expectations but also forecast predicted a drop in its coming quarters. SunPower said in part, “we see a number of near-term industry challenges, primarily in our power plant segment, that we expect to impact our business and financial performance in the second half of 2016. The extension of the Investment Tax Credit, as well as the bonus depreciation credit, while beneficial to the long-term health of the industry, has reduced the urgency to complete new solar projects by the end of 2016, with many customers adopting a longer-term timeline for project completion. Additionally, near-term economic returns have deteriorated due to aggressive PPA pricing by new market entrants, including a number of large, global independent power companies.”

Following this news SunPower stock dropped $4.47 per share, or over 30%, to close at $10.31 on August 10, 2016

The Complaint alleges that throughout the Class Period, Defendants made false and misleading statements and/or failed to disclose: (1) that many of the Company’s customers were adopting a longer-term timeline for project completion; (2) that SunPower’s near-term economic returns were weakening due to forceful PPA pricing by new market competitors; (3) that market disruption in the YieldCo environment was affecting SunPower’s assumptions related to monetizing deferred profits; (4) that the need for SunPower’s products was significantly declining; (5) that SunPower would implement a manufacturing realignment that would result in significant restructuring charges; (6) that the Company’s fiscal year 2016 guidance was inflated; and (7) consequently, SunPower’s statements regarding its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/spwr or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in SunPower you have until October 17, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 444002

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Keryx Biopharmaceuticals Inc. (KERX) & Lead Plaintiff Deadline: October 3, 2016

NEW YORK, NY / ACCESSWIRE / September 28, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District, Southern District of New York, on behalf of those who purchased shares of Keryx Biopharmaceuticals Inc. (“Keryx” or the “Company”) (NASDAQ: KERX) between February 25, 2016 and July 29, 2016 inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

Keryx is a biopharmaceutical company that markets therapies for patients with renal disease. Keryx’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral iron-based compound, that became U.S. Food and Drug Administration (“FDA”) approved in September 2014 to manage serum phosphorus levels in patients with chronic kidney disease (“CKD”) on dialysis.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Keryx’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Keryx was having trouble with its production of converting API to finished drug product; (2) these difficulties were lessening production yields of finished drug product; (3) consequently, Keryx would drain its reserve of finished drug product; and (4) subsequently, Defendants’ statements regarding Keryx’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On August 1, 2016, Keryx revealed that a “production-related issue” at the manufacturer will cause an interruption in the supply Auryxia® (ferric citrate) tablets. Keryx admitted that “current inventories of Auryxia are not sufficient to ensure uninterrupted patient access.” Keryx said that it expects to restore adequate supply of Auryxia and make Auryxia available to patients during the fourth quarter of 2016. Keryx also withdrew its 2016 financial guidance. Following this news, Keryx stock dropped $2.64 per share, or 35.8%, to close at $4.72 on August 1, 2016.

No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/kerx. You can also contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Keryx, you have until October 3, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 443626

SHAREHOLDER ALERT – – Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Warren Resources, Inc. (WRESQ) & Lead Plaintiff Deadline October 11, 2016

NEW YORK, NY / ACCESSWIRE / September 28, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Warren Resources, Inc. (“Warren Resources” or the “Company”) (OTC: WRESQ) and certain of its officers. The class action was filed on behalf of a class consisting of all persons or entities who purchased Warren Resources securities between November 4, 2014 through June 2, 2016, both dates inclusive (the “Class Period”).

The Complaint alleges that throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that Warren Resources was “well positioned” to “ride out” and “successfully navigate” the “market fluctuations,” all while the Company was actually on its way to bankruptcy. Consequentially, defendants’ statements regarding Warren Resources business and operations were false and misleading and/or lacked a reasonable basis. Then on June 2, 2016, Warren Resources filed for Chapter 11 bankruptcy.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/wres or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Warren Resources you have until October 11, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 443707

SHAREHOLDER ALERT – Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Power Solutions International, Inc. (PSIX) and Lead Plaintiff Deadline: October 21, 2016

NEW YORK, NY / ACCESSWIRE / September 28, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed in the United States District Court, Northern District of Illinois, against Power Solutions International, Inc (“Power Solutions” or the “Company”) (NASDAQ: PSIX) and certain of its officers. The class action is on behalf of a class consisting of all persons or entities who purchased Power Solutions securities between May 8, 2015 and August 15, 2016, inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange
Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, and failed to disclose material adverse facts regarding Power Solutions’ business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Power Solutions improperly listed revenue for certain transactions; (2) Power Solutions did not have sufficient controls over financial reporting; and (3) consequently, Power Solutions’ public statements were materially false and misleading at all relevant times.

On August 15, 2016, after-market hours, Power Solutions revealed that it needed an extension to file its quarterly report for the quarter ended June 30, 2016. The Company said that the it has not completed its financial statements “in light of an ongoing review of allegations made by a former employee” regarding “certain transactions involving revenue recognition.” Following this news, Power Solutions dropped $1.52 per share, or 9.85%, to close at $13.91 on August 16, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/psix or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Power Solitions you have until October 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 444160

MAXPlaces Accepting New Clients for Their Long Island SEO Company Services

MAXPlaces Marketing,LLC releases information on how its new Long Island Search Engine Optimization service will change things in the small to medium business space for the better. Further information can be found at http://www.maxplaces.com.

Farmingdale, United States – September 28, 2016 /PressCable/ —

Earlier today, MAXPlaces Marketing, LLC announced the launch of its new Long Island Search Engine Optimization (SEO) service, set to go live Monday, October 3, 2016. For anyone with even a passing interest in expanding their online footprint in the Nassau and/or Suffolk County area, this new development will be worth paying attention to, as it’s set to shake things up.

Anyone who’s spoken to an online marketing company recently will notice most SEO companies offer cookie cutter service options. The Digital Marketing Director at MAXPlaces Marketing, LLC, Brian Winum, makes a point of saying “things are going to change when our Long Island Search Engine Optimization service launches”.

Brian Winum continues… “Where you’ll always see our competitors doing the same old thing, we will strive to work hand-in-hand with you to establish a clear cut marketing solution targeting all your objectives while staying within your budget. We do this because we believe it’s time things were done differently as each client has their own unique needs and goals. Ultimately this is going to be a huge benefit to our customers because it will help clients take their online marketing efforts to the next level.”

MAXPlaces Marketing, LLC was established in September 2014. It has been doing business for two years and it has always aimed to provide Long Island SEO Company services of the highest quality to their clients.

Currently, the closest thing to MAXPlaces Marketing, LLC’s Search Engine Optimization service is traditional public relations marketing, but MAXPlaces improved on this by by taking it to the digital realm. This alone is predicted to make MAXPlaces Marketing, LLC’s Search Engine Optimization service more popular with customers in the Long Island area quickly.

Once again, the Long Island SEO service is set to launch October 3, 2016. To find out more, the place to visit is http://www.maxplaces.com

Contact Info:
Name: Brian Winum
Email: info@maxplaces.com
Organization: MAXPlaces Marketing,LLC
Address: 565 Broadhollow Rd Suite 12E

Release ID: 134679

Cystic Fibrosis Treatment for Fungal Infections in Lungs Reported

TAMPA, FL / ACCESSWIRE / September 28, 2016 / CEOCFO Magazine, an independent investment publication that highlights important technologies and companies, today describes a promising new treatment for fungal infections in the lungs of cystic fibrosis patients.

Up to half of these patients have infections in their lungs caused by a spore-forming mold named Aspergillus fumigatus. Many of those patients, particularly children and young adults, will develop an allergic reaction to the fungus, Bronchopulmonary Aspergillosis (ABPA), according to the Cystic Fibrosis Foundation. Coughing, wheezing and other symptoms can be severe.

Current treatments are oral drugs including itraconazole. The problem is that high doses are needed to get enough of the drug to the lungs. That causes severe side effects that must be managed and monitored-including liver toxicity.

A more effective strategy is to deliver the itraconazole directly to the lungs by breathing it in. That’s the approach taken by Lexington, Mass-based pharmaceutical company Pulmatrix, Inc. (NASDAQ: PULM). Pulmatrix’s innovation was creating small,
dense particles that can be easily inhaled, and combining them with drugs like itraconazole. Pulmatrix’s drug candidate for CF is called PUR1900.

“We’ve urgently needed a way to deliver antifungal drugs directly to the lungs,” said Stanford University CF expert Richard Moss M.D. “Pulmatrix’s PUR1900, using the inhaled dry particle technology, meets that need. It could offer major benefits to CF patients with fungal infections.”

That’s why the U.S. Food & Drug Administration has granted the company’s request for orphan drug status for PUR1900, explaining that the designation “is based on a plausible hypothesis that [the] drug may be clinically superior to the same drug that is already approved.”

While PUR1900 has the potential to improve the lives of cystic fibrosis patients, especially children and young adults, it also could bring significant revenues for Pulmatrix. The estimated cystic fibrosis market alone is tens of thousands of patients a year, and the drug could also find much larger markets treating millions of other pulmonary fungal infections and other immunocompromised patients, making Pulmatrix a strong investment opportunity.

For more information on PUR1900 go to ir.pulmatrix.com and watch the video on https://www.youtube.com/watch?v=t8RgU8YUtjo.

Contact:

Bud Wayne
budwayne@ceocfomagazine.com

SOURCE: CEOCFO Magazine

ReleaseID: 446096